Researchers study light activated anticancer drug targeted to DNA using cisplatin like sub-units

Simple item page
dc.contributor.authorTrulove, Susanen
dc.coverage.spatialBlacksburg, Va.en
dc.date.accessioned2015-10-29T21:06:48Zen
dc.date.available2015-10-29T21:06:48Zen
dc.date.issued2006-03-26en
dc.description.abstractOne of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. However, it also kills healthy tissue. Many scientists are creating alternative drugs or cisplatin analogs in attempts to find treatments without side effects. One approach to analog development is light activated drugs, or photodynamic therapy (PDT). Now a Virginia Tech chemistry-biology research team that has been working on both non-cisplatin drugs and cisplatin analogs has combined their findings to create a molecular complex (supramolecule) that exploits cisplatins tumor targeting to deliver a light activated drug.en
dc.format.mimetypetext/htmlen
dc.identifier.urihttp://hdl.handle.net/10919/59300en
dc.publisherVirginia Tech. University Relationsen
dc.rightsIn Copyrighten
dc.rights.holderVirginia Tech. University Relationsen
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectCollege of Scienceen
dc.titleResearchers study light activated anticancer drug targeted to DNA using cisplatin like sub-unitsen
dc.typePress releaseen
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Name:
2006-141.html
Size:
5.7 KB
Format:
Hypertext Markup Language
Download

Collections

Virginia Tech News